Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What key factors are powering the surge in the macrolide antibiotics market right now?

The dimension of the macrolide antibiotics market has been expanding swiftly over the recent years. The market, valued at $59.07 billion in 2024, is projected to soar to $66.02 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 11.8%. This considerable growth during the preceding years can be credited to the amplifying antibiotic resistance, endorsement of freshly formulated antibiotics, a surge in the prevalence of infectious diseases, and various initiatives undertaken by the government and healthcare sector.

How fast Is the macrolide antibiotics market expected to grow, and what’s its future value?

Rapid expansion is forecasted in the coming years for the macrolide antibiotics market, with an anticipated size of $102.09 billion by 2029 and a compound annual growth rate of 11.5%. Reasons propelling growth within the forecast period include increased respiratory infections, the uptake of combination therapies, a growing global elderly population, enhanced diagnostics and heightened awareness, plus the rise of telemedicine and online pharmacy services. Key trends during the forecast period are expected to be improvements in drug delivery systems and formulations, the creation of new macrolide antibiotics, advancements in telemedicine and remote health services, as well as the introduction of environmentally-friendly manufacturing procedures for macrolide antibiotics.

Get your macrolide antibiotics market report here!

https://www.thebusinessresearchcompany.com/report/macrolide-antibiotics-global-market-report

What are the leading drivers of growth in the macrolide antibiotics market?

The escalation in skin infection incidents is anticipated to stimulate the expansion of the macrolide antibiotics market. Skin infections, characterized by the entry of harmful microorganisms into the skin resulting in inflammation and frequently exhibiting symptoms such as redness, swelling, and pain, are on the rise. This increase can be credited to factors like poor sanitation habits, weakened immune systems, contact with environmental pollutants, resistance to antibiotics, and subpar wound care. Macrolide antibiotics are commonly recommended for addressing skin infections initiated by bacteria like Staphylococcus aureus or Streptococcus pyogenes, especially when there’s an allergy or resistance to penicillin. For example, in September 2022, the UK Health Security Agency (UKHSA), a national executive agency based in the UK, reported that the percentage of Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia occurrences owing to skin and soft tissue infections went up from 25.7% in the financial year April 2020-March 2021 to 33.7% in the financial year April 2021-March 2022. In the case of Methicillin-Sensitive Staphylococcus aureus (MSSA) bacteremia incidents, the percentage rose from 27.2% to 28.5% during the same duration. As a consequence, the rising frequency of skin infections is fueling the macrolide antibiotics market’s growth.

What are the key segments defining the macrolide antibiotics market?

The macrolide antibiotics market covered in this report is segmented –

1) By Drugs: Azithromycin, Clarithromycin, Erythromycin, Fidaxomicin, Telithromycin

2) By Indication: Respiratory Tract Infections, Skin Infections, Sexually Transmitted Infections, Gastrointestinal Infections, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations

4) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Providers

5) By End User: Hospital, Dermatology Clinic, Clinic, Ambulatory Centre, Research Laboratories

Subsegments:

1) By Azithromycin: Oral Tablets, Oral Suspension, Injection

2) By Clarithromycin: Immediate-Release Tablets, Extended-Release Tablets, Oral Suspension

3) By Erythromycin: Tablets, Capsules, Topical Solution, Injection

4) By Fidaxomicin: Oral Tablets

5) By Telithromycin: Oral Tablets

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16472&type=smp

Who are the key players steering the development of the macrolide antibiotics market?

Major companies operating in the macrolide antibiotics market are Pfizer Inc., Roche Holding AG, Merck Sharp & Dohme Corp, AbbVie Inc., Bayer AG, Sanofi S.A, Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc., Eli Lily and Company, Amgen Inc., Teva Pharmaceutical Industries Limited, Mylan N.V., Daiichi Sankyo, Sun Pharmaceutical Industries Limited, Cipla Limited, Lupin Limited, Zydus Lifesciences Limited, Alkem Laboratories Ltd., Zhejiang Guobang Pharmaceutical Co. Ltd., Fresenius Kabi USA, WOCKHARDT, Crescent Pharma Limited, Wellona Pharma Private Limited

What are the key trends shaping the future of the macrolide antibiotics market?

To broaden their market presence, lower treatment charges, and enhance availability, major businesses in the macrolide antibiotic industry are putting efforts into generating generic formulations. Generic versions of macrolide antibiotics are non-branded drugs that maintain the same active components, dosage, and efficacy as the branded counterparts. A case in point is Phantom Pharmaceuticals, an American pharmaceutical firm that, in May 2022, rolled out two products: VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, both tailored for adults with Helicobacter pylori (H. pylori) infection. The triple pack comprises of vonoprazan, a potassium-competitive acid blocker (PCAB), in conjunction with amoxicillin and clarithromycin, while the dual pack incorporates vonoprazan and amoxicillin. These are groundbreaking therapies, as vonoprazan introduces the first fresh category of acid inhibitors approved in the U.S. after a span of more than 30 years.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16472

Which regions are most influential in expanding the macrolide antibiotics market?

North America was the largest region in the macrolide antibiotics market in 2024. The regions covered in the macrolide antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Inhaled Antibiotics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/inhaled-antibiotics-global-market-report

Peptide Antibiotics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/peptide-antibiotics-global-market-report

Carbapenem-Based Antibiotics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/carbapenem-based-antibiotics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: